Methods for treating hair loss disorders

Patent metadata

Field	Value
Publication number	US-9730877-B2
Application number	US-201514821666-A
Country	US
Kind code	B2
Filing date	Aug 7, 2015
Priority date	Nov 2, 2010
Publication date	Aug 15, 2017
Grant date	Aug 15, 2017

Abstract

The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.

First claim

What is claimed is:

1. A method of treating androgenetic alopecia in a mammalian subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a Janus Kinase (Jak) Ca Jak2 Ca Jak3 Ca Signal Transducers and Activators of Transcription (Stat) 1 and/or a Stat 2 inhibitor, wherein said inhibitor is selected from the group consisting of: LY 3009104, tofacitinib (CP690550), INCB 018424, R348, VX-509, PF-956980, AG490, CYT387, SB1518, TG101348, BMS-911543, WP-1034, CEP-701 and JAK3 Inhibitor IV (ZM-39923).

2. The method of claim 1 , wherein the inhibitor is LY3009104.

3. The method of claim 1 , wherein the inhibitor is tofacitinib (CP690550).

4. The method of claim 1 , wherein the inhibitor is R348.

5. The method of claim 1 , wherein the inhibitor is VX-509.

6. The method of claim 1 , wherein the inhibitor is PF-956980.

7. The method of claim 1 , wherein the inhibitor is AG490.

8. The method of claim 1 , wherein the inhibitor is CYT387.

9. The method of claim 1 , wherein the inhibitor is SB1518.

10. The method of claim 1 , wherein the inhibitor is TG101348.

11. The method of claim 1 , wherein the inhibitor is BMS-911543.

12. The method of claim 1 , wherein the inhibitor is WP-1034.

13. The method of claim 1 , wherein the inhibitor is CEP-701.

14. The method of claim 1 , wherein the inhibitor is JAK3 Inhibitor IV (ZM-39923).

15. The method of claim 1 , wherein the subject is a human.

16. The method of claim 15 , wherein the inhibitor is INCB 018424.

17. The method of claim 1 , wherein administering to the subject occurs in a route selected from subcutaneous injection, intra-muscular injection, intra-peritoneal injection, intravenous injection, an infusion, oral, nasal, topical, intradermal, inhalation, transdermal, transmucosal, rectal and a combination thereof.

18. The method of claim 1 , wherein said inhibitor is administered to the subject in a pharmaceutical composition selected from solution, suspension, capsule, tablet, pill, troche, nasal spray, suppository, ointment, salve, gel, and cream.

19. The method of claim 1 , wherein said inhibitor is contained in a topical pharmaceutical composition at a concentration selected from about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1.0%, about 1.1%, about 1.2%, about 1.3%, about 1.4%, about 1.5%, about 1.6%, about 1.7%, about 1.8%, about 1.9%, about 2.0%, about 2.1%, about 2.2%, about 2.3%, about 2.4%, about 2.5%, about 2.6%, about 2.7%, about 2.8%, about 2.9%, or about 3.0%, about 3.5%, about 4%, about 4.5%, about 5%, about 5.5%, about 6%, about 6.5%, about 7%, about 7.5%, about 8%, about 8.5%, about 9%, about 9.5%, and about 10%.

20. The method of claim 1 , wherein the effective amount of said inhibitor administered to the subject is selected from about 1 mg/kg body weight, about 1.5 mg/kg body weight, about 2 mg/kg body weight, about 2.5 mg/kg body weight, about 3 mg/kg body weight, about 3.5 mg/kg body weight, about 4 mg/kg body weight, about 4.5 mg/kg body weight, about 5 mg/kg body weight, about 5.5 mg/kg body weight, about 6 mg/kg body weight, about 6.5 mg/kg body weight, about 7 mg/kg body weight, about 7.5 mg/kg body weight, about 8 mg/kg body weight, about 9.5 mg/kg body weight, about 10 mg/kg body weight, about 10.5 mg/kg body weight, about 11.0 mg/kg body weight, about 11.5 mg/kg body weight, about 12 mg/kg body weight, about 12.5 mg/kg body weight, about 13 mg/kg body weight, about 13.5 mg/kg body weight, about 14 mg/kg body weight, about 14.5 mg/kg body weight, about 15 mg/kg body weight, about 15.5 mg/kg body weight, about 16 mg/kg body weight, about 16.5 mg/kg body weight, about 17 mg/kg body weight, about 17.5 mg/kg body weight, about 18 mg/kg body weight, about 19.5 mg/kg body weight, about 20 mg/kg body weight, about 21.5 mg/kg body weight, about 22 mg/kg body weight, about 22.5 mg/kg body weight, about 23 mg/kg body weight, about 23.5 mg/kg body weight, about 24 mg/kg body weight, about 24.5 mg/kg body weight, about 25 mg/kg body weight, about 25.5 mg/kg body weight, about 26 mg/kg body weight, about 26.5 mg/kg body weight, about 27 mg/kg body weight, about 27.5 mg/kg body weight, about 28 mg/kg body weight, about 29.5 mg/kg body weight, and about 30 mg/kg body weight.

21. The method of claim 1 , wherein administering occurs daily, weekly, twice Weekly, monthly, twice monthly, yearly, 1 time per week, 2 times per week, 3 times per week, 4 times per week, 5 times per week, 6 times per week, 7 times per week, 8 times per week, 9 times per week, 10 times per week, 11 times per week, 12 times per week, 13 times per week, or 14 times per week.

22. The method of claim 1 , wherein administering to the subject occurs for at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 8 weeks, at least 12 weeks, or at least 16 weeks.

Assignees

• Univ Columbia

Inventors

• Christiano Angela M
• Clynes Raphael

Classifications

• A61K31/553

  having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine · CPC title

• A61K2800/782

  Enzyme inhibitors; Enzyme antagonists · CPC title

• A61K8/64

  Proteins; Peptides; Derivatives or degradation products thereof · CPC title

• A61K31/437

  the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline · CPC title

• A61K31/519

  ortho- or peri-condensed with heterocyclic rings · CPC title